2:07 PM
 | 
Dec 03, 2018
 |  BC Extra  |  Company News

NIH may give ElevateBio exclusive CAR T license

NIH's National Cancer Institute is considering granting ElevateBio LLC (Cambridge, Mass.) an exclusive license to develop an undisclosed CAR T therapy targeting FMS-like tyrosine kinase 3 (FLT3; CD135).

In a Federal Registry notice, NIH said it is accepting comments and/or applications for a license for FLT3-specific CAR Ts until Dec. 4. The notice lists two patent applications filed by NCI for development of a FLT3...

Read the full 306 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >